Under a tenth of patients that would benefit from weight-loss injections like Wegovy can access them, caution the World Health Organization as it releases its inaugural guidance on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just access to these injectable treatments.
Per estimates, more than two billion are projected to be living with obesity by 2030 without intervention.
"Our new guidelines recognises that excess weight is a long-term condition that can be addressed with comprehensive and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are key hurdles to widespread availability to the injections that can help people shift substantial weight, explains the body.
GLP-1 Therapy Supply Crisis
Even under the present most optimistic outlook, the production of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of those who need them, per the health organization.
The recommendation calls on nations and manufacturers to increase access, via approaches like licensing agreements.
A patent on a key compound – the main ingredient of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Drugs Function
These medications imitate a natural hormone to slow digestion, suppress the appetite and enhance the sense of being full so individuals consume fewer calories.
People typically begin shedding pounds after several weeks of commencing the regular doses.
Research points to patients may regain a significant portion a year later of stopping the medication, because their normal appetite return.
To be overweight or obese raises your chance for experiencing diseases, including type 2 diabetes, heart disease, stroke, and certain malignancies.
Obesity concerns people in countries worldwide and was linked to millions of deaths worldwide in 2024, according to the health agency.
